LAG3 and neoplasm: Accordingly with these observations, the LAG-3 immune checkpoint has been identified as a potential target to improve productive tumor-specific T cell immunity, and various LAG-3 inhibitors have been developed and their efficacy evaluated both in preclinical models of MPM and in clinical trials.